Fc-optimized GITR antibody enhances a CD4 T cell-dendritic cell crosstalk to promote antitumor immunity.

Fc-optimized human GITR antibody boosts antitumor immunity by enhancing CD4 T cell and dendritic cell interactions, achieving superior therapeutic effects.

• Why it matters: Effective cancer immunotherapy requires precise activation of immune pathways, but the role of Fc domain engagement in human anti-GITR antibodies has been insufficiently understood, limiting their clinical potential.
• What they did: Researchers engineered Fc regions of human anti-GITR monoclonal antibodies to improve FcγR interactions and tested these modifications in humanized mice, focusing on immune activation mechanisms.
• The result: The Fc-optimized antibodies increased regulatory T cell depletion, promoted CD4 T cell and dendritic cell crosstalk, and enhanced CD8 T cell activity, thereby significantly improving antitumor responses.